Lupin Pharmaceuticals has received final approval for its Ranolazine Extended-release tablets, 500 mg and 1000 mg from the United States Food and Drugs Administration (US FDA).
Lupin’s Ranolazine Extended-release tablets are the AB-rated generic equivalent of Gilead Sciences (Gilead) Ranexa Extended-release tablets, 500 mg and 1000 mg strengths. Ranolazine Extended-release tablets is indicated for treatment of chronic angina.
Ranexa tablets, 500 mg and 1000 mg had US sales of approximately $ 443.4 million, for the twelve months ending March, 2013 (IMS Health data).
EP News Bureau – Mumbai
- Advertisement -
